Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1985647 | 1.00 | NPSR1 (0.39) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL4051818 | 0.84 | NPSR1 (0.39) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL30788574 | 0.84 | NPSR1 (0.39) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL15424206 | 0.84 | NPSR1 (0.39) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL1622689 | 0.83 | NPSR1 (0.42) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL28968933 | 0.82 | ALDH1A1 (0.32) | ALDH1A1TSHRPOLB | |
| SCHEMBL7897943 | 0.82 | ALDH1A1 (0.32) | ALDH1A1TSHRPOLB | |
| SCHEMBL13497221 | 0.82 | ALDH1A1 (0.46) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL8009911 | 0.82 | NPSR1 (0.41) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL214459 | 0.74 | NPSR1 (0.56) | NPSR1GLO1ALDH1A1SMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403142-B2 | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | CURIS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| EP-3849554-B1 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11654136-B2 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | CURIS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654136-B2 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | CURIS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220249502-A1 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220249502-A1 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-08-11 | — | — | US | disclosed |
| US-20090093507-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090093507-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090093507-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2009036057-A1 | ANTIPROLIFERATIVE AGENTS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036057-A1 | ANTIPROLIFERATIVE AGENTS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036012-A1 | HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036016-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036016-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076006-A1 | HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090076006-A1 | HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | NPSR1 4690/4885GLO1 4495/4885ALDH1A1 3440/4885 |
| US-20220249502-A1 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | PDPK1, PDCD1, PDCD1LG2 | NPSR1 3828/4885GLO1 4691/4885ALDH1A1 2387/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | NPSR1 4697/4885GLO1 4472/4885ALDH1A1 3415/4885 |
| US-20090093507-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CDK3, CDKL1, CDKL3 | NPSR1 4491/4885GLO1 4510/4885ALDH1A1 2650/4885 |
| US-12403142-B2 | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | PDPK1, PDCD1, PDCD1LG2 | NPSR1 3828/4885GLO1 4691/4885ALDH1A1 2387/4885 |
| US-11654136-B2 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | HDAC1, PI4KA, PDPK1 | NPSR1 4579/4885GLO1 4378/4885ALDH1A1 3452/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | NPSR1 4697/4885GLO1 4472/4885ALDH1A1 3415/4885 |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | NPSR1 4697/4885GLO1 4472/4885ALDH1A1 3415/4885 |
| US-20090076006-A1 | HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | HSP90AB1, HSP90AB2P, HSP90B1 | NPSR1 4505/4885GLO1 3728/4885ALDH1A1 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.